Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| LPCN | Lipocine | $2.01 | -$7.25 | -78.32% | 6.5M | $68M | $1.81$12.37 |
| ELAB | Pmgc | $6.18 | -$7.82 | -55.86% | 19.5M | $7.6M | $1.62$466.20 |
| EEIQ | EpicQuest Education Group International | $7.55 | -$3.03 | -28.64% | 586.2K | $16M | $1.90$27.84 |
| SST | System1 | $3.86 | -$1.37 | -26.15% | 2.3M | $42M | $1.35$15.00 |
| RENX | RenX Enterprises | $1.96 | -$0.65 | -24.90% | 1.3M | $6.1M | $1.42$47.20 |
| FGI | Fgi Industries | $4.04 | -$0.93 | -18.71% | 53.3K | $9.5M | $2.28$12.62 |
| CDT | Cdt Equity | $4.15 | -$0.95 | -18.63% | 113.4K | $902K | $4.08$4,200.00 |
| LVLU | Lulu's Fashion Lounge | $10.90 | -$1.77 | -13.94% | 604 | $35M | $2.98$32.32 |
| FTLF | FitLife Brands | $10.46 | -$1.64 | -13.55% | 33.7K | $114M | $9.83$20.98 |
| SNSE | Sensei Biotherapeutics | $30.26 | -$4.53 | -13.02% | 37.2K | $44M | $5.21$36.76 |
| INBS | Intelligent Bio Solutions | $2.73 | -$0.40 | -12.66% | 1.1M | $6.2M | $2.56$24.90 |
| RVYL | Ryvyl | $5.05 | -$0.73 | -12.63% | 138.9K | $7.3M | $4.14$81.55 |
| UGRO | Urban-gro | $19.25 | -$2.73 | -12.42% | 25.8K | $17M | $2.02$37.00 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $40.90 | -$5.75 | -12.33% | 574.6K | - | $38.62$706.00 |
| YDDL | One And One Green Technologies. | $12.31 | -$1.69 | -12.07% | 502.9K | $756M | $3.61$15.90 |
| ANGO | AngioDynamics | $10.52 | -$1.42 | -11.89% | 57.1K | $492M | $8.36$13.99 |
| LICN | Lichen International | $4.60 | -$0.59 | -11.33% | 116.8K | $85M | $2.57$8.28 |
| ASTC | Astrotech | $4.06 | -$0.39 | -8.76% | 432.9K | $7.8M | $1.92$8.01 |
Related Articles
Featured Article
Should Growth Investors Buy This Revolutionary Small-Cap Stock?
Kody Kester|Jul 25, 2023
The medical devices company is taking an exciting approach to treating some of the most complex diseases.
Wall Street Thinks This Small-Cap Stock Can Double in Value
Kody Kester|Apr 4, 2023
Analysts are projecting a huge rebound from this beaten-down stock in the next 12 months.
Is This Under-the-Radar Growth Stock a Buy?
Kody Kester|Jan 19, 2023
This company is a small player in the steadily growing medtech industry.
Wall Street Thinks This Obscure Growth Stock Could Soar 92% in 2023
Kody Kester|Dec 30, 2022
As COVID-19 headwinds fade, AngioDynamics' business could rebound.
Here's Why This Hidden Growth Stock Is a Buy
Kody Kester|Oct 21, 2022
This medical device company may not be a household name, but it could be an up-and-comer.
Should You Buy This Under-the-Radar Growth Stock?
Kody Kester|Jul 29, 2022
Like the Nasdaq Composite, this little-known medical device stock has been beaten down in 2022.
3 Reasons to Consider Buying This Overlooked Medical Device Stock
Kody Kester|May 1, 2022
The Nasdaq's sell-off looks to have given investors a buying opportunity in this little-known medical device stock.
Is This Small-Cap Medical Devices Stock a Buy?
Kody Kester|Feb 1, 2022
AngioDynamics managed to deliver solid revenue growth in the second quarter despite COVID-19 headwinds.
Is This Under-the-Radar Medical Devices Stock a Buy?
Kody Kester|Nov 3, 2021
The medical devices company beat analyst expectations in the first quarter of its new fiscal year. Could it be a buy?
After Beating Estimates, Is This Little-Known Medical Device Company a Buy?
Kody Kester|Jul 18, 2021
AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?
